TAK-700 (Orteronel)

Catalog No.S1195

TAK-700 (Orteronel) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). Phase 3.

Price Stock Quantity  
In DMSO USD 330 In stock
USD 147 In stock
USD 997 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

TAK-700 (Orteronel) Chemical Structure

TAK-700 (Orteronel) Chemical Structure
Molecular Weight: 307.35

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

TAK-700 (Orteronel) is available in the following compound libraries:

Product Information

  • Compare P450 (e.g. CYP17) Inhibitors
    Compare P450 (e.g. CYP17) Inhibitors
  • Research Area

Product Description

Biological Activity

Description TAK-700 (Orteronel) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). Phase 3.
Targets 17,20-lyase (Rat) 17,20-lyase (Human)
IC50 54 nM [1] 38 nM [1]
In vitro In vitro, TAK-700 shows the potent inhibitory activity against rat and human steroid 17,20-lyase inhibitor with IC50 of 54 nM and 38 nM, respectively. While other CYP isoforms including 11-hydroxylase and CYP3A4 are not significantly affected by TAK-700. [1] In microsomes expressing human CYP isoforms, TAK-700 exhibit greater inhibitory effects on 17,20-lyase with IC50 of 19 nM compared to the other CYP isoforms. [1] TAK-700 shows the inhibitory activity against monkey 17,20-lyase and 17-hydroxylase with IC50 of 27 nM and 38 nM, respectively. [2] In monkey adrenal cells, TAK-700 inhibits the ACTH stimulated production of DHEA and androstenedione with IC50 of 110 nM and 130 nM, respectively. Moreover, TAK-700 also potently inhibits DHEA production in human adrenocortical tumor line H295R cells with IC50 of 37 nM. [2]
In vivo In cynomolgus monkeys, oral treatment of TAK-700 at a dose of 1 mg/kg markedly reduces serum testosterone and dehydroepiandrosterone (DHEA) levels. [1] Oral treatment of TAK-700 at a dose of 1 mg/kg results in favorable pharmacokinetic parameters with Tmax, Cmax, t1/2 and AUC0-24 hours of 1.7 hours, 0.147 μg/mL, 3.8 hours and 0.727 μg h/mL, respectively. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Inhibitory activity on steroid 17,20-lyase in vitro Testes excised from 13-week-old male SD rats are homogenized, and testicular microsomes are prepared by centrifugation. The reaction mixture contained 75 mM phosphate buffer (pH 7.4), 7 μg of the microsome protein, 10 nM [1,2-3H]-17α-hydroxyprogesterone (NEN), 5 mM NADPH (Oriental Yeast), and 1 nM-1000 nM TAK-700 in a total volume of 20 μL at room temperature. The concentration of reagents is expressed as the final concentration in the reaction mixture. TAK-700 is serially diluted with dimethylformamide, and then diluted fivefold with distilled water before 5 μL of the diluted solution is added to the reaction mixture. After incubating for 15 minutes at 37 °C the reaction is terminated by the addition of 40 μL of ethyl acetate, then vortexed for 30 seconds and briefly centrifuged. Thirty microliters of the organic phases are applied to silica gel TLC plates. The substrate and the products, androstenedione and testosterone, are separated using the toluene-acetone (7:2) solvent system. Detection of the spots and measurement of the radioactivity as PSL are performed with a BAS2000 Bio-image analyzer (FUJIX). The concentration of TAK-700 needed to reduce the concentration of the products by 50% (the concentration of the control group in which no TAK-700 is added is taken as 100%) is calculated. Inhibitory activity on human enzymes is determined as described above. The reaction mixture contained 75 mM phosphate buffer (pH 7.4), 1 mM magnesium chloride, 0.5 pmol of recombinant P450c17, 0.5 pmol of recombinant cytochrome b5, 20.8 ng of recombinant NADPH-cytochrome P450 reductase, 10 nM [1,2-3H]-17α-hydroxypregnenolone, 5 mM NADPH (Oriental Yeast), and 1 nM-1000 nM test compound in a total volume of 20 μL. The concentration of reagents is expressed as the final concentration in the reaction mixture. TAK-700 is serially diluted with dimethylformamide, and then diluted fivefold with distilled water before 5 μL of the diluted solution is added to the reaction mixture. After incubating for 15 minutes incubation at 37 °C the reaction is terminated by the addition of 40 μL of ethyl acetate, then vortexed for 30 seconds and briefly centrifuged. Thirty microliters of the organic phases are applied to silica gel TLC plates. The substrate and the product DHEA are separated using the cyclohexane-ethyl acetate (3:2) solvent system.

Animal Study: [1]

Animal Models Adult male cynomolgus monkeys.
Dosages ≤1 mg/kg
Administration Administered via p.o.
Solubility 0.5% methylcellulose, 30 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01709734 Recruiting Prostate Cancer Tokai Pharmaceuticals 2012-12 Phase 2
NCT01809691 Recruiting Prostate Cancer Southwest Oncology Group|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) 2013-03 Phase 3
NCT01816048 Recruiting Prostatic Neoplasms|Prostate Cancer University of Wisconsin, Madison|Millennium Pharmaceuticals, Inc. 2013-05 Phase 2
NCT01866423 Not yet recruiting Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer USC/Norris Comprehensive Cancer Center|National Cancer Institute (NCI) 2013-06 Phase 2
NCT01658527 Not yet recruiting Prostate Cancer European Organisation for Research and Treatment of Cancer - EORTC 2013-09 Phase 2

Chemical Information

Download TAK-700 (Orteronel) SDF
Molecular Weight (MW) 307.35
Formula

C18H17N3O2

CAS No. 426219-18-3
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A
Solubility (25°C) * In vitro DMSO 61 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol 8 mg/mL (26 mM)
In vivo 0.5% methylcellulose, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-e]imidazol-7-yl)-N-methyl-2-naphthamide

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.30735 3.0735 6.147 9.2205

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related P450 (e.g. CYP17) Inhibitors

  • NLG919

    NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.

  • AGI-5198

    AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

  • Apremilast (CC-10004)

    Apremilast (CC-10004) is a potent and orally active PDE4 and TNF-α inhibitor with IC50 of 74 nM and 77 nM, respectively.

  • Abiraterone

    Abiraterone is a potent CYP17 inhibitor with IC50 of 2 nM.

    Features:Approved for the treatment of docetaxel-treated castration-resistant prostate cancer.

  • Abiraterone Acetate

    Abiraterone Acetate is an acetate salt form of Abiraterone which is a steroidal cytochrome CYP17 inhibitor with IC50 of 72 nM.

    Features:Abiraterone is a drug used in castration-resistant prostate cancer.

  • Voriconazole

    Voriconazole is a new triazole derivative similar to fluconazole and itraconazole that acts by inhibiting fungal cytochrome P-450-dependent, 14-alpha-sterol demethylase-mediated synthesis of ergosterol.

  • Avasimibe

    Avasimibe inhibits ACAT with IC50 of 3.3 μM, also inhibits human P450 isoenzymes CYP2C9, CYP1A2 and CYP2C19 with IC50 of 2.9 μM, 13.9 μM and 26.5 μM,

  • Ketoconazole

    Ketoconazole inhibits cyclosporine oxidase and testosterone 6 beta-hydroxylase with IC50 of 0.19 mM and 0.22 mM, respectively.

    Features:More active than both Econazole and Miconazole against Malassezia species.

  • Apigenin

    Apigenin is a potent P450 inhibitor for CYP2C9 with IC50 of 23 pM.

    Features:Much more potent than kaempferol and myricetin in CT-L inhibition.

  • TAK-700 (Orteronel)

    TAK-700 (Orteronel) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). Phase 3.

Recently Viewed Items

Tags: buy TAK-700 (Orteronel) | TAK-700 (Orteronel) supplier | purchase TAK-700 (Orteronel) | TAK-700 (Orteronel) cost | TAK-700 (Orteronel) manufacturer | order TAK-700 (Orteronel) | TAK-700 (Orteronel) distributor
Contact Us